Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Journal of Clinical Oncology|2021Cited by 81
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyNizar M. Tannir, Michael E. Hurwitz, Daniel C. Cho et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 27
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain MetastasesDebu Tripathy, Cláudia Vieira, Mary Tagliaferri et al.|JAMA Oncology|2022Cited by 24
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02Arlene O. Siefker‐Radtke, Nizar M. Tannir, Daniel C. Cho et al.|European Urology|2022Cited by 20
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 studyAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7